Granted, the paper doesn't touch on, much less settle, the AI bubble debate. Even real productivity enhancements have a price, and it could be that the hyperscalers and AI companies have overestimated ...
A green light would have made Vyglxia the first and only FDA-approved treatment for spinocerebellar ataxia, a life-threatening neurodegenerative disease characterized by progressive loss of voluntary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback